Clinical Trial Update: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) [Phase 2]

View source ↗

Summary

A Phase 2 study comparing DNIB0600A to pegylated liposomal doxorubicin in platinum-resistant ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• DNIB0600A
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Genentech, Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED